Stable on Stelara? Fight for continued coverage as biosimilars enter the market.

Fight Your Stelara Formulary Removal

Some major PBMs are removing Stelara in 2025-2026, but you can appeal for continuity of care.

Understanding Your Stelara (Ustekinumab) Continuity of Care Denial

Health Alliance, Navitus, UnitedHealthcare, and other plans are removing Stelara from formularies in 2025-2026 as multiple ustekinumab biosimilars enter the market. If you've been stable on Stelara and your insurer wants you to switch to a biosimilar, you have rights under federal continuity of care regulations.

Common Reasons for Denial

  • ! Stelara removed from formulary — biosimilar required
  • ! Plan requires switch to Steqeyma, Yesintek, or other biosimilar
  • ! Stelara no longer covered at current tier
  • ! Prior authorization now required for Stelara
  • ! Non-formulary exception denied

How We Help

We help you document your treatment history with Stelara, explain why biosimilar switching may be harmful in your case, and cite federal and state laws that protect stable patients from forced medication changes.

Some Types of Evidence We Can Use For Supporting Your Appeal

Ustekinumab (Stelara) has demonstrated long-term efficacy and safety in psoriasis, psoriatic arthritis, and inflammatory bowel disease.

Non-medical switching of stable patients from biologic originators to biosimilars may carry risks of altered efficacy or immunogenicity.

Pharmacy Discount Options

Stelara is usually expensive even with discount cards, so the appeal is your primary path to coverage. Discount programs below may still reduce the cost somewhat, but check the price before assuming they make the drug affordable.

GoodRx (opens in a new tab)

Free discount card accepted at most US pharmacies. Compare prices across nearby pharmacies and present the GoodRx coupon at the counter.

Mark Cuban Cost Plus Drugs (opens in a new tab)

Mail-order pharmacy with transparent pricing (manufacturer cost + 15% markup + dispensing fee). Carries many common generics.

Amazon Search (opens in a new tab)

Search Amazon's main retail site for over-the-counter formulations or supplies related to this medication. (This is Amazon's general product search, not the prescription Amazon Pharmacy storefront; Prime members may see discounted prices.)

Important: amounts paid out-of-pocket through discount programs typically do NOT count toward your insurance deductible or out-of-pocket maximum. Continue your appeal to get the medication covered through insurance.

Patient Assistance & Copay Programs

These programs may help reduce your costs while you appeal:

Janssen CarePath Savings Program

Eligible patients with commercial insurance may pay as little as $5 per dose. Not for government insurance.

Johnson & Johnson Patient Assistance Foundation

Patient assistance for uninsured or underinsured patients who meet income requirements.

Eligibility requirements and program terms may change. Please verify current details directly with each organization.

Patient Advocacy & Support Organizations

These organizations provide education, support, and advocacy for patients:

Crohn's & Colitis Foundation

Leading nonprofit for IBD research and patient support.

National Psoriasis Foundation

Patient advocacy for psoriasis and psoriatic arthritis.

Frequently Asked Questions

Multiple ustekinumab biosimilars entered the market in 2024-2025, and PBMs are negotiating deals to prefer lower-cost biosimilar options. By early 2026, most major PBMs will have removed Stelara from national formularies.

Timelines vary: Health Alliance removed Stelara April 2025, Navitus/OptumRx in July 2025, UnitedHealthcare in September 2025, and Blue KC/Express Scripts in January 2026. Check with your specific plan for details.

Common preferred biosimilars include Steqeyma, Yesintek, and private-label versions from Lumicera (OptumRx) and Quallent (Express Scripts). Plans may differ in which specific biosimilar they prefer.

Yes. You can request a non-formulary exception. However, some plans may require you to pay the difference in cost between Stelara and the preferred biosimilar.

Ready to Fight Your Stelara (Ustekinumab) Continuity of Care Denial?

Our free AI-powered tool will help you generate a compelling appeal letter in minutes.

Disclaimer: Fight Health Insurance is not affiliated with, endorsed by, or partnered with any pharmaceutical manufacturer, healthcare provider, medical device company, or patient assistance program. All information provided is for educational and informational purposes only and does not constitute medical or legal advice. Please consult with your healthcare provider regarding treatment options and with your insurance company regarding coverage decisions.